Live

A

$ABUS

2 articles found

1 positive

0 negative

1 neutral

Moderna's $2.25B Settlement Clears Patent Cloud as Biotech Sector Eyes Deep Value Opportunities

Investing.com

Investing.com·Mar 5·David Wagner

Moderna's $2.25B Settlement Clears Patent Cloud as Biotech Sector Eyes Deep Value Opportunities

Moderna settles $2.25B patent dispute, surges 15.99%. Analysis identifies 9 biotech stocks trading 27-65% below fair value with 31-251% upside potential.

MRNAROIVABUSfair valueundervalued

Moderna Settles $950M Patent Dispute, Clears Path for Profitability Push

Benzinga

Benzinga·Mar 4·Vandana Singh

Moderna Settles $950M Patent Dispute, Clears Path for Profitability Push

Moderna settles $950M patent dispute with Arbutus and Genevant, clearing legal uncertainty. Stock surges 8.85% as company targets 2028 breakeven with $4.5-5B cash by 2026.

MRNABNTXROIVABUSbalance sheet strengthmRNA technology